Noninvasive approaches for detecting and monitoring bladder cancer

References

• Letašiová S, Medve’ová A, Šovčíková A, et al. Bladder cancer, a review of the environmental risk factors. Environ Health 2012;11(Suppl 1):S11
   PubMed Web of Science ®Google Scholar
• Meliker JR, Nriagu JO. Arsenic in drinking water and bladder cancer: review of epidemiological evidence. Trace Metal Contam Environ 2007;9:551-84
   Google Scholar
• Larsson SC, Andersson SO, Johansson JE, Wolk A. Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 2008;44:2655-60
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Shao C, Keane TE, et al. Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. Int J Cancer 2012;131:158-64
   PubMedGoogle Scholar
• Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93
   PubMed Web of Science ®Google Scholar
• Cheung G, Shai A, Bilia M, et al. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med 2013;11:1-8
   PubMedGoogle Scholar
• Zeegers MPA, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 2004;21:392-401
   PubMed Web of Science ®Google Scholar
• Case RAM, Hosker ME. Tumours of the urinary bladder as an occupational disease in the rubber industry in England and Wales. Br J Prev Soc Med 1954;8:39-50
   PubMedGoogle Scholar
• Navarro Silvera SA, Rohan TE. Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 2007;18:7-27
   PubMed Web of Science ®Google Scholar
• Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008;101:11-19
   PubMed Web of Science ®Google Scholar
• Noon AP, Catto JWF. Bladder cancer in 2012, Challenging current paradigms. Nat Rev Urol 2013;10:67-8
   PubMedGoogle Scholar
• Hernández S, Toll A, Baselga E, et al. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol 2007;127:1664-6
   PubMedGoogle Scholar
• Wolff EM, Liang G, Jones PA. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2:502-10
   PubMedGoogle Scholar
• Lorenzo Romero JG, Salinas Sánchez AS, Giménez Bachs JM, et al. p53 Gene mutations in superficial bladder cancer. Urol Int 2004;73:212-18
   PubMedGoogle Scholar
• Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006;106:1205-16
   PubMedGoogle Scholar
• Stone R, Sabichi AL, Gill J, et al. Identification of Genes Correlated with Early-Stage Bladder Cancer Progression. Cancer Prev Res 2010;3:776-86
   PubMed Web of Science ®Google Scholar
• Wang G, Chan ES, Kwan BC, et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 2012;10:106-13
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Lee S, Choi W, et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 2010;28:429-40
   PubMed Web of Science ®Google Scholar
• Ahirwar D, Kesarwani P, Manchanda PK, et al. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genet Cytogenet 2008;184:1-8
   PubMedGoogle Scholar
• Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010;28:409-28
   PubMed Web of Science ®Google Scholar
• Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009;106:14016-21
   PubMed Web of Science ®Google Scholar
• Brandt WD, Matsui W, Rosenberg JE, et al. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev 2009;28:291-304
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736-48
   PubMed Web of Science ®Google Scholar
• Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol 2012;188:361-8
   PubMedGoogle Scholar
• Herman MP, Svatek RS, Lotan Y, et al. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol 2008;60:217-35
   PubMedGoogle Scholar
• Shariat SF, Karam JA, Lotan Y, et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 2008;10:120-35
   PubMedGoogle Scholar
• Quek ML, Stein JP, Nichols PW, et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 2005;174:103-6
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25:152-65
   PubMed Web of Science ®Google Scholar
• Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5:e13821
   PubMed Web of Science ®Google Scholar
• Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;5:581-93
   Google Scholar
• Phase II study of TKI258 in advanced urothelial carcinoma. Available from: http://clinicaltrials.gov/show/NCT00790426
   Google Scholar
• Marsit CJ, Koestler DC, Christensen BC, et al. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol 2011;29:1133-9
   PubMed Web of Science ®Google Scholar
• Amaral AF, Méndez-Pertuz M, Muñoz A, et al. Spanish Bladder Cancer/EPICURO Study investigators. Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. J Natl Cancer Inst 2012;104:1897-904
   PubMedGoogle Scholar
• Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr Opin Urol 2011;21:420-7
   PubMedGoogle Scholar
• Yun SJ, Kim W-J. Role of the epithelial-mesenchymal transition in bladder cancer: from prognosis to therapeutic target. Korean J Urol 2013;54:645-50
   PubMedGoogle Scholar
• Chen J, Gao Y, Xu B, et al. NOV is upregulated and promotes migration and invasion in bladder cancer. Tumour Biol 2014;35(7):6749-55
   PubMedGoogle Scholar
• Raimondi C, Gradilone A, Gazzaniga P. Circulating tumor cells in early bladder cancer: insight into micrometastatic disease. Expert Rev Mol Diagn 2014;14:407-9
   PubMed Web of Science ®Google Scholar
• Kim YH, Kim WT, Jeong P, et al. Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2. J Korean Med Sci 2014;29:351-6
   PubMed Web of Science ®Google Scholar
• Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010;70:7017-26
   PubMed Web of Science ®Google Scholar
• Kawashima A, Nakayama M, Kakuta Y, et al. Excision repair cross-complementing group1 (ERCC1) may predict the efficacy of chemoradiotherapy for bladder cancer. Clin Cancer Res 2011;17:2561-9
   PubMed Web of Science ®Google Scholar
• Feldman AS, Banyard J, Wu CL, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 2009;15:1024-31
   PubMed Web of Science ®Google Scholar
• Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22:139-44
   PubMed Web of Science ®Google Scholar
• Moreira JM, Ohlsson G, Gromov P, et al. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics 2010;9:161-77
   PubMed Web of Science ®Google Scholar
• Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 2011;121:132-47
   PubMed Web of Science ®Google Scholar
• Czarnecka A, Golik P, Bartnik E. Mitochondrial DNA mutations in human neoplasia. J Appl Genet 2006;47:67-78
   PubMed Web of Science ®Google Scholar
• Guney AI, Ergec DS, Tavukcu HH, et al. Detection of mitochondrial DNA mutations in nonmuscle invasive bladder cancer. Genet Test Mol Biomarkers 2012;16:672-8
   PubMed Web of Science ®Google Scholar
• Carew J, Huang P. Mitochondrial defects in cancer. Mol Cancer 2006;1:1-12
   Google Scholar
• Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 2006;25:4663-74
   PubMed Web of Science ®Google Scholar
• Kroemer G. Mitochondria in cancer. Oncogene 2006;25:4630-2
   PubMed Web of Science ®Google Scholar
• Sanchez-Cespedes M, Parrella P, Nomoto S, et al. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 2001;61:7015-19
   PubMed Web of Science ®Google Scholar
• Parrella P, Seripa D, Matera MG, et al. Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett 2003;190:73-7
   PubMed Web of Science ®Google Scholar
• Jakupciak JP, Wang W, Markowitz ME, et al. Mitochondrial DNA as a cancer biomarker. J Mol Diagn 2005;7:258-67
   PubMed Web of Science ®Google Scholar
• Kim MM, Clinger JD, Masayesva BG, et al. Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Cancer Res 2004;10:8512-15
   Google Scholar
• Lièvre A, Blons H, Houllier AM, et al. Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. Br J Cancer 2006;94:692-7
   PubMed Web of Science ®Google Scholar
• Uzawa K, Baba T, Uchida F, et al. Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma. Oncotarget 2012;3:670-7
   PubMed Web of Science ®Google Scholar
• Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017-19
   PubMed Web of Science ®Google Scholar
• Maitra A, Cohen Y, Gillespie SE, et al. The Human MitoChip: a highthroughput sequencing microarray for mitochondrial mutation detection. Genome Res 2004;14:812-19
   PubMed Web of Science ®Google Scholar
• Chen GF, Chan FL, Hong BF, et al. Mitochondrial DNA mutations in chemical carcinogen-induced rat bladder and human bladder cancer. Oncol Rep 2004;12:463-72
   PubMed Web of Science ®Google Scholar
• Wada T, Tanji N, Ozawa A, et al. Mitochondrial DNA mutations and 8-hydroxy-2’-deoxyguanosine Content in Japanese patients with urinary bladder and renal cancers. Anticancer Res 2006;26:3403-8
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Hoque MO, Upadhyay S, Sidransky D. Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res 2008;68:700-6
   PubMed Web of Science ®Google Scholar
• Paepe BD. Mitochondrial markers for cancer: relevance to diagnosis, therapy, and prognosis and general understanding of malignant disease mechanisms. ISRN Pathol 2012;2012:1-15
   Google Scholar
• Chan MW, Chan LW, Tang NL, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104(5):611-16
   PubMed Web of Science ®Google Scholar
• Capello F, David S, Ardizzone N, et al. Expression of heat shock proteins HSP10, HSP27, HSP60, HSP70, and HSP90 in urothelial carcinoma of urinary bladder. J Cancer Mol 2006;2:73-7
   Google Scholar
• Phillips T. The role of methylation in gene expression. Nature Education 2008;1:116
   Google Scholar
• Lim DHK, Maher ER. DNA methylation: a form of epigenetic control of gene expression. Obstet Gynaecol 2010;12:37-42
   Google Scholar
• Kandimalla R, van Tilborg AA, Zwarthoff EC. DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol 2013;10:327-35
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Chandrasoma S, Siegmund KD, et al. Prognostic relevance of methylation markers in patients with non- muscle invasive bladder carcinoma. Eur J Cancer 2005;41:2769-78
   PubMed Web of Science ®Google Scholar
• Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70
   PubMed Web of Science ®Google Scholar
• Andrew AS, Gui J, Sanderson AC, et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet 2009;125:527-39
   PubMed Web of Science ®Google Scholar
• Dulaimi E, Uzzo RG, Greenberg RE, et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Houseman EA, Christensen BC, et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS One 2010;5:e12334
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev Mol Diagn 2009;9:259-69
   PubMed Web of Science ®Google Scholar
• Reinert T, Modin C, Castano FM, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011;17:5582-92
   PubMed Web of Science ®Google Scholar
• Guancial EA, Bellmunt J, Yeh S, et al. The evolving understanding of microRNA in bladder cancer. Urol Oncol 2014;32:41.e31-40
   Google Scholar
• Dyrskjøt L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009;69:4851-60
   PubMed Web of Science ®Google Scholar
• Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009;125:345-52
   PubMed Web of Science ®Google Scholar
• Zabolotneva AA, Zhavoronkov A, Garazha AV, et al. Characteristic patterns of microRNA expression in human bladder cancer. Front Genet 2013;3:310
   PubMedGoogle Scholar
• Han Y, Chen J, Zhao X, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011;6:e18286
   PubMed Web of Science ®Google Scholar
• Pignot G, Cizeron-Clairac G, Vacher S, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 2013;132:2479-91
   PubMed Web of Science ®Google Scholar
• Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2012;31:1701-8
   PubMed Web of Science ®Google Scholar
• Available from: http://ghr.nlm.nih.gov/condition/bladder-cancer
   Google Scholar
• Available from: www.cancerresearchuk.org/about-cancer/type/bladder-cancer/treatment/bladder-cancer-stage-and-grade
   Google Scholar
• Bryan RT, Zeegers MP, James ND, et al. Biomarkers in bladder cancer. BJU Int 2010;105:608-13
   PubMedGoogle Scholar
• Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer. Histopathol 2010;57:1-13
   PubMed Web of Science ®Google Scholar
• Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol 2011;9:41-51
   PubMed Web of Science ®Google Scholar
• Matsushita K, Cha EK, Matsumoto K, et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol 2011;18:616-29
   PubMed Web of Science ®Google Scholar
• Otto W, Denzinger S, Fritsche HM, et al. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: Single-center analysis of eight biomarkers in a series of three hundred six patients. Clin Genitourin Cancer 2013;11:537-44
   PubMedGoogle Scholar
• Utting M, Werner W, Dahse R, et al. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res 2002;8:35-40
   PubMedGoogle Scholar
• Berendsen CL, Mulder TP, Peters WH. Plasma glutathione S-transferase pi 1-1 AND alpha 1-1 levels in patients with bladder cancer. J Urol 2000;164:2126-8
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Shariat SF, Casella R, et al. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol 2003;170:2248-52
   PubMed Web of Science ®Google Scholar
• Szarvas T, Hoffmann F, Becker M, et al. Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification? Urologe A 2011;50:64-70
   PubMedGoogle Scholar
• Gallagher DJ, Milkowsky MI. Circulating Tumor Cells: a Potential Bladder Cancer Biomarker? EJCMO 2010;2:105-10
   Google Scholar
• Pode D, Shapiro A, Wald M, et al. Noninvasive detection of bladder with the BTAstat test. J Urol 1999;161:443-6
   PubMed Web of Science ®Google Scholar
• Goodison S, Chang M, Dai Y, et al. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One 2012;7:e47469
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Millholland JM, Zwarthoff EC, et al. A noninvasive multianalyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients. Res Rep Urol 2012;4:17-26
   PubMedGoogle Scholar
• Sugiyama M, Woodman A, Sugino T, et al. Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine. Clin Mol Pathol 1995;48:M142-7
   PubMedGoogle Scholar
• Mohammed MA, Seleim MF, Abdalla MS, et al. Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urol 2013;13:25-30
   PubMedGoogle Scholar
• Wadhwa N, Jatawa SK, Tiwari A. Non-invasive urine based tests for the detection of bladder cancer. J Clin Pathol 2012;65:970-5
   PubMedGoogle Scholar
• Arisan S. The importance of molecular tumor markers for bladder cancer. Turk J Canc 2003;33:171-6
   Google Scholar
• Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol 2008;53:909-16
   PubMed Web of Science ®Google Scholar
• Cheng ZZ, Corey MJ, Pärepalo M, et al. Complement factor H as a marker for detection of bladder cancer. Clin Chem 2005;51:856-63
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Nesi G, Baroni G, et al. p16(INK4a) expression in urinary bladder carcinoma. Arch Ital Urol Androl 2006;78:97-100
   PubMedGoogle Scholar
• Burchardt M, Burchardt T, Shabsigh A, et al. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000;46:595-605
   PubMed Web of Science ®Google Scholar
• Skagias L, Politi E, Karameris A, et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years’ research. JBUON 2009;14:457-62
   Google Scholar
• Staack A, Badendieck S, Schnorr D, et al. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol 2006;6:19-23
   PubMedGoogle Scholar